Self-assembled nanocomplex between polymerized phenylboronic acid and doxorubicin for efficient tumor-targeted chemotherapy by Lee, Junseok et al.
Acta Pharmacologica Sinica  (2017) 38: 848–858 
www.nature.com/aps
Original Article
Self-assembled nanocomplex between polymerized 
phenylboronic acid and doxorubicin for efficient 
tumor-targeted chemotherapy
Junseok LEE1, #, Jinhwan KIM1, 2, #, Yeong Mi LEE2, Dongsik PARK2, Sooseok IM3, Eun Ho SONG2, Hansoo PARK4, 
Won Jong KIM1, 2, 3, *
1Center for Self-assembly and Complexity, Institute of Basic Science (IBS), Pohang 37673, Republic of Korea; 2Department of 
Chemistry, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea; 3School of Interdisciplinary 
Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea; 4School 
of Integrative Engineering, Chung-Ang University, Seoul 156–751, Republic of Korea
Abstract 
Since the discovery that nano-scaled particulates can easily be incorporated into tumors via the enhanced permeability and retention 
(EPR) effect, such nanostructures have been exploited as therapeutic small molecule delivery systems. However, the convoluted 
synthetic process of conventional nanostructures has impeded their feasibility and reproducibility in clinical applications. Herein, 
we report an easily prepared formulation of self-assembled nanostructures for systemic delivery of the anti-cancer drug doxorubicin 
(DOX). Phenylboronic acid (PBA) was grafted onto the polymeric backbone of poly(maleic anhydride). pPBA-DOX nanocomplexes were 
prepared by simple mixing, on the basis of the strong interaction between the 1,3-diol of DOX and the PBA moiety on pPBA. Three 
nanocomplexes (1, 2, 4) were designed on the basis of [PBA]:[DOX] molar ratios of 1:1, 2:1, and 4:1, respectively, to investigate 
the function of the residual PBA moiety as a targeting ligand. An acid-labile drug release profile was observed, owing to the intrinsic 
properties of the phenylboronic ester. Moreover, the tumor-targeting ability of the nanocomplexes was demonstrated, both in vitro by 
confocal microscopy and in vivo by fluorescence imaging, to be driven by an inherent property of the residual PBA. Ligand competition 
assays with free PBA pre-treatment demonstrated the targeting effect of the residual PBA from the nanocomplexes 2 and 4. Finally, the 
nanocomplexes 2 and 4, compared with the free DOX, exhibited significantly greater anti-cancer effects in vitro and even in vivo. Our 
pPBA-DOX nanocomplex enables a new paradigm for self-assembled nanostructures with potential biomedical applications.
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Introduction
Self-assembly is a natural process in which disordered com-
ponents are spontaneously assembled into a certain structure 
or pattern[1].  Non-covalent interactions such as hydrogen 
bonding, van der Waals interactions, and electrostatic inter-
actions are major driving forces of self-assembly[2–4].  In par-
ticular, nano-sized and self-assembled structures are one of 
the most useful materials to provide various functionalities 
in biomedical applications[5–8].  For instance, the nano-sized 
and self-assembled structures are highly useful for the deliv-
ery of hydrophobic anti-cancer drugs because of their facile 
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formulation.  In addition, these structures exhibit the unique 
property of accumulating within the tumor site because of 
their enhanced permeability and retention (EPR) effect[9–13]. 
Therefore, various formulations such as liposomes, polymeric 
micelles, polymersomes, and inorganic-organic hybrids have 
been developed and evaluated over the course of decades 
for use in biomedical applications[14–18].  Doxorubicin (DOX) 
is a one of the most commonly used anti-cancer chemothera-
peutics for various types of cancer, including blood, breast, 
lung, and ovarian cancers[19–22].  The molecular structure of 
DOX comprises two characteristic parts: the hydrophobic tet-
racycline ring and an amine-functionalized sugar.  Although 
DOX is administered intravenously as an aqueous solution of 
the hydrochloride salt, several studies have reported hemo-
lytic activity of DOX, resulting from its cationic charge and 
hydrophobicity[23–25].  To improve the blood compatibility of 
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DOX and extend its circulation time in the blood, liposomal 
formulations have been introduced and recently commercial-
ized, including Doxil®, Myocet®, and Caelyx® [26–29].  However, 
there are concerns about non-specific leakage from liposomes 
and polymeric micelles during blood circulation, which can 
be driven by large dilution and decreased stability under high 
salt conditions.  Therefore, a more stable nanoparticle system 
is still needed for the efficient delivery of DOX to enhance the 
drug’s efficacy and limit its side effects[30–32].  In that regard, 
the distinct chemical features of DOX, such as its hydropho-
bicity and cationic charge, have been exploited for loading 
DOX into delivery cargos such as the hydrophobic core of 
liposomes, polymeric micelles, or nanoparticles[18, 33–37].  Fur-
ther, DOX has been adsorbed on the surface of carbon nano-
materials and intercalated into specific DNA sequences via π-π 
interaction[17, 38–41].  Charge interaction with negatively charged 
materials such as the surface of silica or polyanions is another 
common strategy utilized for loading DOX[42, 43].  However, 
such systems impede the precise control of drug loading, and 
complicated chemical modification is required in many cases. 
Here, we approached this issue from a different direction 
from the approaches used in previous studies.  The molecular 
structure of DOX contains a 9-(2-hydroxyacetyl) group and the 
9S-hydroxyl group, which comprise a 1,3-diol conformation. 
Notably, phenylboronic acid (PBA) has a remarkable binding 
affinity toward 1,2-cis-diols and 1,3-diols via the formation of 
a boronic ester[44–47].  Therefore, strong binding between PBA 
and DOX was expected and provided clues to a new strategy 
for formulatinge self-assembled nanostructures.
Recently, our group has reported the self-assembled archi-
tecture between PBA-grafted polyethyleneimine (PEI) and 
sugar-grafted PEI via the formation of a phenylboronic ester, 
and has found that the resultant products exhibit feasible gene 
delivery efficacy[48].  We have also reported nanocomplexes of 
entangled poly-paclitaxel (pPTX) and poly-cyclodextrin (pCD) 
via the self-assembly of a CD::PTX inclusion complex for the 
enhanced aqueous solubility and delivery of PTX[40].  Extend-
ing our previous studies, here we developed a nanocomplex 
between polymerized PBA (pPBA) and DOX and evaluated 
that nanocomplex both in vitro and in vivo.  PBA was grafted 
onto the backbone of poly(maleic anhydride) by a spontane-
ous ring opening reaction to achieve pPBA.  Because neither 
catalysts nor toxic organic solvents were utilized, the synthetic 
strategy of pPBA demonstrated atom economy and green 
chemistry[49].  Through the simple process of mixing aqueous 
solutions of pPBA and DOX, self-assembled pPBA-DOX nano-
complexes were generated via the hydrophobic interaction 
between the PBA-DOX pairs.  Furthermore, DOX was easily 
released at the intracellular pH, owing to the pH sensitivity 
of the boronic ester, and further destruction was observed 
(Scheme 1).  A remarkable therapeutic effect is expected from 
our rationally designed pPBA-DOX nanocomplexes both in 
vitro and in vivo: because 1) the circulation time in vivo can 
be extended by blocking non-specific interactions with blood 
components, owing to the negative charge from the residual 
carboxylic group, 2) the suitable size of the nanocomplexes 
enables effective tumor accumulation via the EPR effect in vivo, 
3) the remaining PBA moieties can be exploited as a tumor-
targeting ligand, and 4) DOX can be released in response to 
the intracellular environment.  Consequently, a simple but 
efficient pPBA-DOX nanocomplex would provide a fascinat-
ing strategy for the delivery of conventional drugs not only in 
anti-cancer therapy but also in broader treatment methods.
Scheme 1.  Schematic illustration for formulation and destruction of pPBA-DOX nanocomplex.  Formulation of nanocomplex is driven by charge interac-
tion and the boronic ester formation between phenylboronate of pPBA and 1,3-diol of DOX.  At an acidic pH, destruction of nanocomplex is induced by 
decreased affinity of boronic ester, and finally DOX is released.
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Materials and methods
Reagents
Poly(methyl vinyl ether-alt-maleic anhydride) (pMA; Mn 
~80 000 g/mol), 3-aminophenylboronic acid (PBA-NH2) 
monohydrate, and thiazolyl blue tetrazolium bromide (MTT) 
were purchased from Sigma-Aldrich (St Louis, MO, USA). 
FCR648-NH2 was purchased from BioActs (Korea).  Doxoru-
bicin (DOX) was purchased from Wako Chemical (Japan).  All 
reagents were used as received without further purification.
Instrumental methods
Transmission electron microscopy (TEM) images were taken 
using a transmission electron microscope (JEM-2210, JEOL) 
and analyzed using Gatan DigitalMicrograph software.  UV-
vis absorbance for the MTT assay was measured using a 
microplate spectrofluorometer (VICTOR3 V multilabel coun-
ter), and fluorescence spectra were obtained from a spectro-
fluorophotometer (RF-5301 PC, Shimadzu) or multi-well plate 
reader (SpectraMax® i3, Molecular Devices).  Hydrodynamic 
size and zeta potential were measured using a Zetasizer 
(Nano S90, Nano Z, respectively; Malvern) at 0.1 mmol/L in 
Dulbecco’s phosphate-buffered saline (DPBS, pH 7.4) or 0.1 
mol/L acetate buffer (pH 5.5).  The confocal laser scanning 
microscope (CLSM) images were obtained using an Olympus 
FV-1000 and analyzed using the Olympus FluoView ver 1.7 
software.
Preparation of poly(phenylboronic acid-co-maleic anhydride) 
(pPBA)
PBA-conjugated pMA (pPBA) was prepared by spontane-
ous amide coupling of the acid anhydride moiety onto the 
pMA backbone and -NH2 of PBA-NH2 via a ring opening 
reaction (Scheme S2).  Briefly, 500 mg of pMA (3.2 mmol 
anhydride eq) and 160 mg of PBA-NH2 (1 mmol) were 
dissolved in 15 mL of dry dimethyl sulfoxide (DMSO) 
and stirred at room temperature (RT) overnight.  Unre-
acted succinic anhydride moieties were hydrolyzed by 
adding 10 mL of 0.1 mol/L NaOH and dialyzed against 
deionized water for two days (molecular weight cut-
off=10 000), followed by lyophilization.  The molar ratio of 
conjugated PBA was calculated by 1H NMR (yield: 91%). 
1H NMR (D2O, 300 MHz): 7.7–7.0 (m, Ph, 4xH); 3.8–3.5 (m, 
–CH–, 1H); 3.5-3.1 (m, –OCH3, 3H); 3.1–2.4 (m, anhydride, 2H); 
2.4–1.4 (m, –CH2–, 2H).
For various imaging experiments in vitro and in vivo, red flu-
orescence dye was conjugated onto the pPBA backbone in the 
same manner.  In brief, 200 mg of pMA, 70 mg of PBA-NH2, 
and 5 mg of FCR648-NH2 were fully dissolved in 15 mL of dry 
DMSO and stirred at RT overnight.  Then, 10 mL of 0.1 mol/L 
NaOH was added and dialyzed against water for two days 
(molecular weight cutoff=10 000), and this was followed by 
lyophilization.  The conjugation ratio of PBA was calculated 
from the 1H NMR (yield: 95%).
As a control polymer that contains no PBA moiety, pMA 
was hydrolyzed by NaOH and dissolved in DPBS to obtain 
hydrolyzed poly(maleic anhydride) (pMAh) solution.  For the 
controlled experiment, [COO–] from the hydrolyzed succinic 
anhydride subunit was equalized from both pPBA and pMAh 
solutions.
Formulation of pPBA-DOX nanocomplexes
The pPBA-DOX nanocomplexes were simply prepared by 
mixing the pPBA and DOX solutions.  For nanocomplexes 
with [PBA]:[DOX] molar ratios of 1:1, 2:1, or 4:1 (nanocom-
plexes 1, 2, and 4, respectively) containing 2 mmol/L DOX 
equivalent, 200 μL of 10 mmol/L DOX was added into 100, 
200, or 400 μL of 20 mmol/L pPBA, respectively.  Then, 100 μL 
of 10× PBS (pH 7.4) was added to the solution, and the vial 
was filled to 1 mL with deionized water.  For the quenching 
assay, pPBA was fixed at 1 mmol/L, and the amount of DOX 
varied.  For the quenching assay of DOX, DOX was fixed at 1 
mmol/L, and the amount of pPBA varied.  For the formula-
tion of dye-labeled nanocomplexes, non-labeled pPBA and 
FCR648-labeled pPBA were mixed at the ratio of 1:1 and 1:3 
for the formulation of nanocomplexes 2 and 4, respectively, to 
normalize the fluorescence intensity.
Stimuli-responsive drug release
Drug release from nanocomplexes 1, 2, and 4 at pH 7.4 and 5.5 
was monitored by the inherent fluorescence of DOX (Ex=495 
nm, Em=590 nm).  Within a desired time interval, the solution 
was centrifuged (13 500 r/min, 5 min), and the fluorescence of 
the supernatant was measured.  The amount of released DOX 
was calculated as [(released drug)/(loaded drug)×100].
In vitro cell viability test
To evaluate the therapeutic efficiency of the nanocomplexes, 
the cytotoxicity of the nanocomplexes or control samples was 
measured with MTT assays.  Cells (human breast cancer cells, 
MCF-7 and human prostate cancer cells, PC-3) were seeded on 
a 96-well culture plate at a density of 8000 cells/well and incu-
bated overnight.  Fresh medium was treated with either pPBA 
at a final concentration of 0 to 40 μmol/L, free DOX, or nano-
complexes 1, 2, and 4 at a final equivalent DOX concentration 
of 0 to 10 μmol/L.  The medium was then incubated with the 
cells for another 48 h.  After incubation, the cell viability was 
evaluated with MTT assays.
For the MTT assays, cells were washed with DPBS, and the 
medium was replaced with 200 μL of MTT solution in the 
medium (0.5 mg/mL).  After incubation in the dark for 4 h, 
the medium was removed thoroughly, and purple crystals 
were completely dissolved by 200 μL of DMSO.  Each sample 
(100 μL) was transferred into a new 96-well plate, and UV-vis 
absorbance was measured at 570 nm using a microplate spec-
trofluorometer (VICTOR3 V multilabel counter).  The relative 
percentages of non-treated cells were used to represent 100% 
cell viability.
Competition assay in vitro
The PBA-mediated uptake of nanocomplexes was evaluated 
with competitive assays.  Cells (MCF-7 or PC-3) were seeded 
on a 96-well culture plate at a density of 8000 cells/well and 
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incubated overnight.  After being washed with DPBS, the cells 
were incubated with pre-treated serum-free medium with 
or without 5 mmol/L PBA-NH2 for 30 min.  Then, cells were 
washed and incubated with serum-free medium treated with 
0 to 40 μmol/L pPBA, free DOX, or nanocomplexes 1, 2, and 4 
at a final equivalent DOX concentration of 0 to 10 μmol/L for 
4 h.  Cells were washed and further incubated for 44 h, then 
the cell viability was measured with MTT assays.
Intracellular uptake of nanocomplexes by confocal laser scann-
ing microscopy (CLSM)
The intracellular uptake of nanocomplexes with or without 
competitor was analyzed by confocal microscopy imaging. 
Briefly, MCF-7 or PC-3 cells (100 000 cells/well) were seeded 
on glass coverslips placed in a 12-well culture plate.  Cells 
were incubated overnight and incubated for 30 min with pre-
treated serum-free medium with or without 5 mmol/L PBA-
NH2 as a competitor.  Then, the medium was replaced with 
fresh serum-free medium containing 2 μmol/L DOX equiva-
lent of pPBA or nanocomplexes 1, 2, and 4 and further incu-
bated for 4 h.  To observe the localization of pPBA, FCR648-
labeled pPBA was incorporated and diluted with pPBA to 
control the fluorescence intensity.  Cells were washed with 
DPBS and fixed immediately with 10% neutrally buffered for-
malin at 4 °C overnight.  Cells on the coverslips were mounted 
with Vectashield anti-fade mounting medium containing 
4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) (Vec-
tor Labs).  The intracellular fluorescence of pPBA-FCR648 and 
DOX was observed by CLSM at excitation/emission wave-
lengths of 633/647 and 488/530 nm, respectively.
Hemolysis assay
Hemolysis of each sample was evaluated by measuring the 
released hemoglobin from the erythrocytes.  Briefly, fresh 
mouse blood was prepared in a heparin tube and diluted ten-
fold by DPBS, and this was followed by centrifugation (2000 
r/min, 15 min) to isolate the red blood cells (RBCs).  RBCs 
were diluted, and samples (pPBA, DOX, nanocomplexes 1, 
2, and 4) were added with a final concentration of 1 mmol/L 
DOX equivalent.  The suspensions were incubated at 37 °C for 
4 h and then centrifuged (2000 r/min, 15 min) to separate the 
RBC pellet.  The absorbance of the supernatant at 400 nm was 
measured to minimize the absorbance of released DOX and 
maximize the absorbance of hemoglobin.  Saline and 1× lysis 
buffer were considered to represent 0 and 100% hemolysis, 
respectively.
In vivo biodistribution of pPBA-DOX
Nanocomplexes
All animal experiments were approved by the POSTECH 
Biotech Center Ethics Committee.  CT-26 cells (1 000 000 cells/
mouse) were inoculated subcutaneously (sc) into the flanks of 
female Balb/c mice.  After the average tumor volume reached 
approximately 300 mm3, saline, FCR648-labeled pPBA, nano-
complexes 1, 2, and 4 (3 mg/kg DOX) were systemically 
injected.  Nanocomplexes 2 and 4 were formulated with the 
same molar ratio of FCR648-labeled pPBA and the rest with 
non-labeled pPBA to normalize the fluorescence signal.  At 
24 h post-injection, the fluorescence intensities of the mice and 
tumors were measured with an IVIS spectrum small-animal 
in vivo imaging system at Pohang Technopark Biotech Center 
(Califer Lifescience, Hopkinton, MA, USA).  For the ex vivo 
imaging of DOX, saline, free DOX, and nanocomplex 4 (3 mg/
kg) were injected, and the epifluorescence of DOX from the 
tumor was compared using IVIS imaging in the same manner.
Anti-tumor study in a mouse model
CT26/FLuc cells (1 000 000 cells/mouse) were inoculated 
sc into the flanks of female Balb/c mice.  When the average 
tumor volume reached approximately 300 mm3, the mice were 
divided randomly into 6 groups (7 mice per group).  The mice 
were then injected with 200 μL of each sample: 1) saline, 2) 
pPBA, 3) free DOX, 4) nanocomplex 1, 5) nanocomplex 2, and 
6) nanocomplex 4 (3 mg/kg DOX at d 0 and 4), and the tumor 
volume was monitored every day after the systematic injection 
of the samples.  Tumor volumes were recorded following the 
equation for a prolate ellipsoid of ab2/2, where a is the longest 
and b is the shortest dimension.  Tumor growth was moni-
tored until the tumor was ulcerated, at which time the mice 
were sacrificed according to the rules of the POSTECH Bio-
tech Center Ethics Committee.  All data were represented as 
the mean±SEM, and all significant differences were analyzed 
with OriginPro 8.  The tumor inhibition rate was calculated as 
the ratio between the final and initial volumes of the tumor. 
Perfect tumor inhibition (100%) was set as total growth regres-
sion, and 0% tumor inhibition was set as the growth rate of the 
saline-treated group.  For imaging the tumor, luciferin sub-
strate was injected intraperitoneally immediately before in vivo 
imaging, and the luminescence of the tumor was imaged after 
10 min.  The image was obtained and analyzed with IVIS.
Results
Preparation and characterization of pPBA
Briefly, polymerized PBA (pPBA) was synthesized by chemi-
cal conjugation between 3-aminophenylboronic acid (PBA-
NH2) and poly(maleic anhydride) (pMA).  The conjugation 
ratio was 156 PBA moieties per 513 maleic anhydride subunits, 
as calculated by 1H NMR from the ratio between the aromatic 
region of PBA and –CH2– of the polymer backbone (Figure S1). 
The Fourier transform infrared spectra of pMA and pPBA also 
indicated the successful conjugation of PBA and the hydro-
lysis of the anhydride, which were represented by the disap-
pearance of the acid anhydride peaks (1830–1800 cm-1 and 
1775–1740 cm-1) and the appearance of both carboxylic acid 
(1730–1700 cm-1) and amide (1680–1630 cm-1) of pPBA (Figure 
S2)[50].
Preparation and characterization of the pPBA-DOX nano-
complexes
For the next step, pPBA-DOX nanocomplexes were read-
ily prepared by simple mixing, on the basis of the strong 
interaction between the 1,3-diol of DOX and the PBA moiety 
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on pPBA.  Three different nanocomplexes (1, 2, and 4) were 
designed on the basis of molar ratios of 1:1, 2:1, and 4:1 (PBA 
to pPBA:DOX), respectively, to investigate the function of the 
residual PBA moiety as a targeting ligand.  The sizes of the 
nanocomplexes were measured at the sub-hundred nanometer 
scale (Figure 1A).  As a control, hydrolyzed pMA (pMAh) was 
mixed with DOX, thus resulting in severe aggregation and 
precipitation and indicating that the PBA-diol interaction is 
a major driving force in the formation of the nanocomplexes 
(Figure S3).  To further validate the formation of boronic ester, 
the fluorescence of pPBA was measured, because the steady-
state quenching of the inherent fluorescence of PBA is induced 
by the formation of the boronic ester[48].  The boronic ester 
was quantitatively formed by mixing pPBA with DOX, thus 
suggesting that residual PBA moieties exist and may have 
functioned as a targeting ligand (Figure S4A).  In addition, the 
formation of the hydrophobic core was demonstrated by the 
fluorescence of DOX because DOX fluorescence is quenched 
by π–π stacking[34].  As expected, noticeable quenching of the 
DOX fluorescence was observed, thereby suggesting π-π stack-
ing of DOX at the hydrophobic core of the nanocomplexes 
(Figure S4B).
pH-responsive properties of nanocomplexes
Because the phenylboronic ester linkage shows pH-sensitive 
behavior, pH-responsive drug release and structural deforma-
tion of the nanocomplexes were expected (Scheme S3).  At 
a neutral pH, all three nanocomplexes exhibited a hydrody-
namic size of approximately 80 nm, whereas the size distri-
bution increased to approximately 200 nm at an acidic pH 
(Figure 1A).  In addition, TEM imaging confirmed that the 
condensed structure of nanocomplexes 1, 2, and 4 at neutral 
pH was deformed at acidic pH, corresponding to the data 
obtained from dynamic light scattering (Figure 1C, 1D, S3C-
D).
Given the change in size distribution, the pH-responsive 
drug release profile of pPBA-DOX nanocomplexes was mea-
sured at pH 7.4 and 5.5 (Figure 1B).  At endosomal pH, all 
three nanocomplexes showed 70%–80% drug release in 24 h. 
In contrast, 20%, 40%, and 30%, respectively, were released 
from nanocomplexes 1, 2, and 4 at physiological pH.  Interest-
ingly, nanocomplexes 2 and 4 were less pH-responsive, in con-
trast to the dramatic pH-responsive release of nanocomplex 
1, probably as a result of a combinatorial effect of increased 
charge interaction between the carboxylic group on the pMA 
backbone and DOX as well as the increased hydrophobicity of 
pMA at acidic pH (Figure S5B).
In vitro cytotoxicity and tumor targeting
The cytotoxicity of the materials was evaluated in vitro to dem-
onstrate the therapeutic effect of the nanocomplexes (Figure 
2).  The toxicity of pPBA was negligible because of the highly 
Figure 1.  Physicochemical characterization of nanocomplexes.  (A) Size distribution of nanocomplex 1, 2 and 4.  (B) Drug release profile of nanocomplex 1, 
2 and 4 at pH 7.4 and 5.5.  TEM images of nanocomplex 4 at (C) pH 7.4 and (D) pH 5.5.  
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negative charge of the polymer backbone and biocompatibility 
(Figure S5B).  In the MCF-7 human breast cancer cell line, the 
IC50 value of free DOX was measured as 3.1 μmol/L, and the 
IC50 values of nanocomplexes 1 and 2 were 2.3 and 2.1 μmol/L, 
respectively (Figure 2A).  Surprisingly, nanocomplex 4 exhib-
ited an IC50 value of 0.85 μmol/L DOX equivalent, which was 
3.6-fold more effective than that of free DOX and was possibly 
due to the targeting effect of the residual PBA moieties.  Simi-
lar results were observed in the PC-3 human prostate cancer 
cell line (Figure 2B).
To verify the targeting effect of the residual PBA from nano-
complexes 2 and 4, ligand competition assays were conducted. 
As expected, the toxicity of pPBA and DOX was not affected 
by pre-treatment with PBA (Figure S6).  In addition, the cyto-
toxicity of nanocomplex 1 was not influenced by additional 
ligands, whereas the cytotoxicity of nanocomplexes 2 and 
4 decreased significantly with the pre-treatment of the free 
ligands (Figure 3).
To further investigate the PBA-mediated uptake, confocal 
microscopy images were taken with or without pre-treatment 
of free PBA.  For quantitative microscopic imaging, some 
portions of pPBA were replaced by FCR648-labeled pPBA 
(FCR648-pPBA), and the fluorescence per nanocomplex 
was equalized with the addition of non-labeled pPBA.  As 
expected, the cellular uptake of nanocomplex 4 was mostly 
inhibited by the pre-treatment with free PBA, corresponding 
to the cytotoxic effect observed in the competition assay (Fig-
ures 4, S7, and S8).  In addition, the uptake of pPBA was not 
significantly affected by competitive inhibitors, thus indicating 
that the formation of a condensed structure is an effective fac-
tor for efficient uptake (Figure S9).
In vivo tumor targeting
Before evaluation of the anti-tumor effect of the nanocom-
plexes in vivo, the blood compatibility of the nanocomplexes 
was evaluated by hemolysis assays (Figure S10).  Significant 
hemolysis was induced by free DOX, whereas none of the 
pPBA materials exhibited hemolysis, owing to their negative 
charge.
Given that the in vitro targeting ability of pPBA materials 
was confirmed, the in vivo biodistribution was next determined 
to demonstrate the targeting effect of the nanocomplexes. 
FCR648-pPBA (4 mmol/L) or FCR648-labeled nanocomplexes 
of 1 mmol/L DOX equivalence were systemically injected, 
and their distribution was observed after 24 h by whole-
Figure 2.  In vitro cytotoxicity of pPBA, DOX, nanocomplex 1, 2 and 4 stud-
ied in (A) MCF-7 and (B) PC-3 cell line. *P<0.05, **P<0.01.
Figure 3.  Competition assay in vitro.  Cytotoxicity of nanocomplex 1, 2 and 
4 studied in (A) MCF-7 and (B) PC-3 cell line with or without pre-treatment 
of PBA-NH2. **P<0.01.
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body fluorescence imaging (Figure 5).  The accumulation of 
nanocomplexes was significantly enhanced as the amount of 
residual pPBA was increased.  Quantitatively, nanocomplex 4 
exhibited a 2.5-fold stronger signal from the tumor region than 
did nanocomplex 1.  In addition, most of the fluorescence sig-
nal from the pPBA-injected mice was observed at the kidney. 
Similarly, ex vivo images of each tumor showed significant 
contrast in the epifluorescence (Figure 5B and 5D).  Further-
more, an accumulation of DOX was detected by ex vivo imag-
ing of the tumor site, and a higher level of DOX was observed 
in the tumor treated with nanocomplex 4 h than in the tumor 
treated with free DOX (Figure S11).
In vivo anti-tumor effect
To evaluate the therapeutic effect of pPBA-DOX nanocom-
plexes in vivo, tumor growth in CT26/FLuc-inoculated 
allograft mice was monitored after the injection of saline, 
pPBA, free DOX, and nanocomplexes 1, 2, and 4 (3 mg/kg 
DOX equivalent) at days 0 and 4 (Figure 6A).  The tenden-
cies for tumor growth between saline- and pPBA-injected 
mice were similar, and certain levels of anti-tumor effect were 
observed in mice treated with DOX and nanocomplex 1.  As 
expected, nanocomplexes 2 and 4 exhibited the most signifi-
cant anti-tumor effect, as compared with the other samples.  In 
addition, none of the treated groups showed abrupt changes 
in body weight (Figure S12A).
After monitoring of the tumor growth, the viability of the 
grown tumor was evaluated by assessing the inherent lucif-
erase expression of CT26/FLuc (Figure 6B and 6C).  The 
luciferase activity in the CT26/FLuc tumor was significantly 
diminished in mice treated with nanocomplexes 1 to 4.  In 
Figure 4.  Competition assay in vitro.  (A) Nanocomplex 1, (B) nanocomplex 
2 and (C) nanocomplex 4-treated MCF-7 cell line with or without pre-
treatment of PBA-NH2 were analyzed by confocal microscopy.  Blue images 
represent nucleus, red images represent pPBA in nanocomplexes, and 
green images represent DOX.
Figure 5.  (A) In vivo bio-distribution of saline, pPBA, nanocomplex 1, 2 and 4 after 24 h injection and (B) Ex vivo images of corresponding tumors.  The 
average epi-fluorescence from (C) in vivo nanocomplexes treated tumor site and (D) ex vivo corresponding tumors. **P<0.01 vs Nanocomplex 1.
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agreement with previous in vitro and in vivo results, the lucif-
erase activities in the tumors from saline- and pPBA-treated 
mice were similar, whereas the luciferase activity in the DOX-
treated group declined significantly (Figure S12C).
Discussion
Drug delivery systems using nano-sized complexes have been 
developed to improve the aqueous stability of drug molecules 
and to enhance their accumulation at the tumor site via the 
EPR effect.  For higher efficacy and clinical translation, the 
nanocomplexes need to be conveniently formulated, to be sta-
ble during blood circulation and to be able to internalize target 
sites, specifically by using targeting ligands.  In most cases, 
however, complicated chemical modifications are required to 
achieve the criteria mentioned above, thus limiting the repro-
ducibility of results for clinical translation.  In this study, the 
binding of PBA with DOX through their chemical structures 
provides a simple strategy not only for the formulation of 
nanocomplexes but also for the targeted delivery system.
From that perspective, we formulated tumor-targeting 
self-assembled nanocomplexes, using polymerized PBA and 
DOX.  Briefly, polymerized PBA (pPBA) was synthesized 
by simple mixing of 3-aminophenylboronic acid (PBA-NH2) 
and poly(maleic anhydride) (pMA) via the spontaneous ring 
opening reaction of the succinic anhydride moiety, and this 
was followed by hydrolysis of the remaining anhydride moi-
eties to obtain carboxylic acids.  In the next step, pPBA-DOX 
nanocomplexes were formulated through simple mixing by 
exploiting the interaction between the 1,3-diol of DOX and the 
PBA moiety on pPBA.  Both passive targeting by proper size 
(50–200 nm) measured by dynamic light scattering and active 
targeting by the PBA moiety, which has high binding affinity 
to sialylated epitopes on tumor cells, were expected[51–53].  To 
verify the formation of nanocomplexes from the formation of 
a phenylboronic ester, hydrolyzed pMA (pMAh) was mixed 
with DOX in the same manner as in the control group.  A clear 
nanocomplex solution was achieved from the pPBA group, 
whereas severe aggregation and precipitation were observed 
in all nanocomplexes formulated by pMAh, thus indicating 
that the PBA-diol interaction is a major driving force in the 
formation of the nanocomplexes.
As previously mentioned, the formation of a phenylboronic 
ester bond is highly responsive to environmental pH.  The 
ester bond is particularly labile at acidic pH, such as that in 
the endosomal environment, whereas the bond itself is stable 
under physiological conditions.  Therefore, a pH-responsive 
drug release and structural deformation of nanocomplexes 
were expected.  At neutral pH, all three nanocomplexes exhib-
ited a hydrodynamic size of approximately 80 nm, which is 
suitable for drug delivery.  Furthermore, dramatic changes in 
size distribution were observed in all three nanocomplexes 
at acidic pH from sub-hundred nanometers to approximately 
200 nm, owing to three possible explanations: 1) at acidic pH, 
boronic ester becomes labile, and DOX is easily released from 
the hydrophobic core of the nanocomplex; 2) the solubility 
of DOX is significantly increased at acidic pH because of the 
protonation of the amine moiety; and 3) the hydrophobicity of 
pPBA is increased by the protonation of carboxylic acid on the 
hydrolyzed pMA backbone, as inferred from the decreased 
size in acidic condition in Figure S5A.
pPBA-DOX nanocomplexes were designed for the effective 
delivery of DOX by passive targeting from the EPR effect and 
active targeting from residual PBA moieties.  The cytotoxicity 
of the nanocomplexes was significantly higher than that of the 
Figure 6.  In vivo anti-tumor study.  (A) Tumor growth of CT26/FLuc bearing Balb/c mice.  Error bars represent±SEM.n=7.**P<0.01.  (B) Representa tive 
luminescence image from CT26/FLuc tumor of nanocomplex 1, 2 and 4 injected mice and (C) corresponding ex vivo image. 
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DOX in vitro, possibly as a result of the suitable size for uptake 
and targeting.  To verify the targeting effect by the residual 
PBA of nanocomplexes 2 and 4, a ligand competitive assay 
was designed as follows.  Free PBA was pre-treated to occupy 
the sialylated epitope to inhibit the PBA-mediated uptake of 
the nanocomplexes.  No significant differences were observed 
from the cytotoxicity of nanocomplex 1, regardless of the 
existence of pre-treatment, thus suggesting that no additional 
PBA moieties could be utilized as targeting ligands after the 
formulation of the nanocomplexes.  Moreover, a significant 
inhibition of cytotoxicity was observed from nanocomplexes 2 
and 4 pre-treated with ligands.  Similar results were obtained 
by confocal microscopy, thus demonstrating the function of 
ligand-mediated uptake via the PBA moiety and the sialylated 
epitope in cancer cells.  Additionally, the importance of nano-
sized structures in cellular uptake was verified by confocal 
microscopy.
In this study, pPBA-DOX nanocomplexes with a high molar 
ratio of pPBA were designed to enhance the targeting effect 
by residual PBA moieties.  Moreover, the formation of specific 
structures has been revealed to be an important factor for suc-
cessful cellular uptake.  Therefore, the efficient delivery of 
nanocomplexes in vivo was expected.  To ensure blood com-
patibility after introduction in vivo, hemolysis of the nano-
complexes was evaluated.  Because of the positive charge and 
strong hydrophobicity of DOX, a certain level of hemolysis 
was induced by free DOX.  However, none of the pPBA mate-
rials exhibited hemolysis because of their negative charge.
For the next step, the biodistribution of the nanocomplexes 
was monitored by fluorescence imaging to confirm the in vivo 
targeting effect.  The accumulation of nanocomplexes was sig-
nificantly enhanced as the amount of residual pPBA increased. 
Quantification by average epifluorescence of the tumor site 
showed that nanocomplex 4 exhibited a 2.5-fold stronger sig-
nal in comparison with nanocomplex 1.  Although an equal 
amount of pPBA (4 mmol/L) was injected, interestingly, rela-
tively low tumor accumulation was observed in the pPBA-
injected mice compared with those injected with nanocomplex 
4.  Instead, most of the fluorescence signal from pPBA-injected 
mice was observed at the kidney rather than at the tumor site. 
Similarly, ex vivo images of each tumor showed a significant 
contrast in the epifluorescence due to the different targeting 
abilities of the three nanocomplexes.  These results indicate 
that 1) free pPBA is secreted, 2) accumulation at the tumor site 
requires the formation of certain structures, and 3) accumula-
tion at the tumor site can be enhanced by an additional target-
ing ligand.
As mentioned above, the formation of nanocomplexes 
enabled the successful accumulation at the tumor site in 
vivo through both passive targeting from the EPR effect and 
active targeting from the residual PBA moieties.  Moreover, 
the nanocomplexes exhibited an excellent anti-cancer effect 
in vitro.  Overall, the results from the in vitro study and the in 
vivo biodistribution strongly suggest the potential of the nano-
complexes as an efficient anti-tumor agent.  From our anti-
tumor study in vivo, the tendency of tumor growth between 
saline- and pPBA-injected mice was similar, thereby indicating 
that pPBA itself had no therapeutic effect.  Because DOX itself 
is a practical anti-cancer drug, a certain level of anti-tumor 
activity was observed.  However, the systemic administration 
of DOX still carries the risk of systemic toxicity, owing to the 
hemolytic property, as demonstrated by the hemolysis assays, 
and the possibility of non-specific delivery.  The tumor growth 
observed in mice treated with nanocomplex 1 was similar 
to that in mice treated with free DOX.  As expected, nano-
complexes 2 and 4 exhibited the most significant anti-tumor 
effect compared with the other samples.  These results can be 
explained by the advantages of precisely designed pPBA-DOX 
nanocomplexes described above: 1) extended blood circulation 
time due to strong negative charge, 2) successful accumula-
tion at the tumor site from both the EPR effect and targeting 
effect, 3) enhanced uptake, owing to the existence of residual 
PBA moieties, and 4) successful intracellular pH-responsive 
DOX release after uptake.  Similar results were obtained by 
the luciferase assay of grown tumors, thus suggesting the anti-
tumor effect of the nanocomplexes at the histological level.  In 
addition, the changes in the body weights of all sample-treated 
mice indicated that none of the samples induced severe sys-
temic toxicity at the administered doses.
In conclusion, whereas most of the previously designed 
DOX delivery vehicles have been focused on charge interac-
tion or hydrophobic interaction, our approach takes advantage 
of a different phenomenon, the specific formation of a boronic 
ester between the 1,3-diol of DOX and the phenylboronic acid 
of pPBA.  Despite its ease of preparation, our pPBA-DOX 
nanocomplex exhibited strong anti-tumor effect both in vitro 
and in vivo.  The improved therapeutic effect of the nanocom-
plexes can be explained by tumor targeting via the EPR effect, 
active targeting via the enhanced cellular uptake by residual 
PBA moieties, and cargo release in the intracellular environ-
ment.  Together, the overall results from the in vitro and in vivo 
studies suggest promising therapeutic potential of pPBA-DOX 
nanocomplexes in biomedical applications.
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